Asian shares fell Monday and U.S. futures and the dollar weakened after Moody’s Ratings downgraded the sovereign credit ...

Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...

On Wall Street, Charter Communications rose 1.8% after it said it agreed to merge with Cox Communications in a deal that ...

U.S. stocks rose again to close out their winning week. The S&P 500 climbed 0.7% Friday for a fifth straight gain and pulled ...

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the ...

Wall Street is heading toward the finish of a strong week on Friday as U.S. stocks drift close to the all-time high they set just a few months earlier, though it may feel like an economic era ago.

It was a ‘mutual agreement,’ Novo says in a statement. A search for Fruergaard Jørgensen’s successor is ongoing.

CEO Lars Fruergaard Jørgensen will step down after eight years at the helm of the Danish pharmaceutical giant responsible for ...

"Considering the recent market challenges, the share price decline, and the wish from the Novo Nordisk Foundation, the Novo Nordisk Board and Lars Fruergaard Jørgensen have jointly concluded that ...

Jorgensen became CEO in January 2017 and the company’s market capitalization has more than tripled during his tenure. Novo was first to market with Wegovy and its sister drug Ozempic for diabetes, but ...

"Considering the recent market challenges, the share price decline, and the wish from the Novo Nordisk Foundation, the Novo Nordisk board and Lars Fruergaard Jorgensen have jointly concluded that ...